Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso) in Subjects With Pulmonary Arterial Hypertension

Next Previous
X
Search
Trial Profile

A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso) in Subjects With Pulmonary Arterial Hypertension

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esuberaprost (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms BEAT
  • Sponsors Lung Biotechnology

    • Most Recent Events

    • 08 Apr 2019 Status changed from active, no longer recruiting to discontinued because Beat study did not meet its primary endpoint of delayed time to first clinical worsening event, so company has decided to discontinue further esuberaprost development, according to a United Therapeutics Corporation media release.
    • 08 Apr 2019 According to a United Therapeutics Corporation media release, primary endpoint (Time to clinical worsening defined as time from randomization to the first of any of the events described below) has not been met.
    • 02 Jan 2019 Planned End Date changed from 1 Oct 2018 to 1 Mar 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top